Skip to content

Study · Case report or series · n = 1 · 2026

6 results

Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction.

Ohkuma T, Aotani R, Sakamoto W, Oshiro A, Ago T

Journal of diabetes investigation31 Mar 2026

PMID41914136 (opens in a new tab)PMCIDPMC13238849 (opens in a new tab)DOI10.1111/jdi.70300 (opens in a new tab)PepBankPUB-41914136
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with KCNJ11-related permanent neonatal diabetes, HbA1c stayed between 6.1% and 6.5% on semaglutide 0.25 mg/week.

    In plain wordsIn one woman with a rare inherited diabetes, blood sugar control stayed steady on a low weekly semaglutide dose.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c on semaglutide
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.25 mg/weekAs given in this study (human).

    Measurements

    HbA1c
    6.1 to 6.5%
    semaglutide 0.25 mg/week

    Source sentences

    Summary
    HbA1c remained between 6.1% and 6.5% on semaglutide 0.25 mg/week
    1 context sentence
    Summary · context
    We describe a woman with KCNJ11-related PNDM who achieved insulin discontinuation after adding sitagliptin, followed by further improvement with semaglutide during a five-year follow-up.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with KCNJ11-related permanent neonatal diabetes, the glibenclamide dose fell by 60% while on semaglutide.

    In plain wordsIn one woman with a rare inherited diabetes, the dose of her sulfonylurea drug could be cut by 60% on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlibenclamide dose reduction
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.25 mg/weekAs given in this study (human).

    Measurements

    Glibenclamide reduction
    60%
    on semaglutide

    Source sentences

    Summary
    with a 60% reduction in glibenclamide
    1 context sentence
    Summary · context
    We describe a woman with KCNJ11-related PNDM who achieved insulin discontinuation after adding sitagliptin, followed by further improvement with semaglutide during a five-year follow-up.
  3. 03HumanCase report or seriesEfficacy outcome

    In a woman with KCNJ11-related permanent neonatal diabetes, endogenous insulin secretion was preserved on semaglutide.

    In plain wordsIn one woman with a rare inherited diabetes, her own insulin secretion stayed intact on semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeEndogenous insulin secretion
    Study

    n = 1

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    0.25 mg/weekAs given in this study (human).

    Source sentences

    Summary
    preserved endogenous insulin secretion.
    1 context sentence
    Summary · context
    We describe a woman with KCNJ11-related PNDM who achieved insulin discontinuation after adding sitagliptin, followed by further improvement with semaglutide during a five-year follow-up.
  4. 04HumanCase report or seriesEfficacy outcome

    In a woman with KCNJ11-related permanent neonatal diabetes, HbA1c rose transiently after semaglutide was interrupted and improved after it was resumed.

    In plain wordsIn one woman with a rare inherited diabetes, blood sugar control worsened briefly when semaglutide stopped and improved when it restarted.

    Peptide
    Semaglutide
    Outcome
    MixedHbA1c after semaglutide interruption and resumption
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.25 mg/weekAs given in this study (human).

    Source sentences

    Summary
    A transient HbA1c rise after semaglutide interruption, followed by improvement upon resumption, confirmed its reversible effect.
    1 context sentence
    Summary · context
    We describe a woman with KCNJ11-related PNDM who achieved insulin discontinuation after adding sitagliptin, followed by further improvement with semaglutide during a five-year follow-up.
  5. 05HumanCase report or seriesSafety outcome

    In a woman with KCNJ11-related permanent neonatal diabetes on semaglutide, no episodes of severe hypoglycemia occurred.

    In plain wordsIn one woman with a rare inherited diabetes on semaglutide, there were no episodes of severe low blood sugar.

    Peptide
    Semaglutide
    Outcome
    No significant changeSevere hypoglycemia
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.25 mg/weekAs given in this study (human).

    Source sentences

    Summary
    No episodes of severe hypoglycemia or gastrointestinal adverse events occurred.
    1 context sentence
    Summary · context
    We describe a woman with KCNJ11-related PNDM who achieved insulin discontinuation after adding sitagliptin, followed by further improvement with semaglutide during a five-year follow-up.
  6. 06HumanCase report or seriesSafety outcome

    In a woman with KCNJ11-related permanent neonatal diabetes on semaglutide, no gastrointestinal adverse events occurred.

    In plain wordsIn one woman with a rare inherited diabetes on semaglutide, there were no stomach or bowel side effects.

    Peptide
    Semaglutide
    Outcome
    No significant changeGastrointestinal adverse events
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.25 mg/weekAs given in this study (human).

    Source sentences

    Summary
    No episodes of severe hypoglycemia or gastrointestinal adverse events occurred.
    1 context sentence
    Summary · context
    We describe a woman with KCNJ11-related PNDM who achieved insulin discontinuation after adding sitagliptin, followed by further improvement with semaglutide during a five-year follow-up.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.